MAP2K7 and colorectal carcinoma: The combination of encorafenib and cetuximab with nivolumab leads to an ORR of 45% in patients with MSS,51 BRAFV600E metastatic CRC in a phase I/II trial leading to a randomized phase II.51,78 The same success was not achieved in 2 studies with atezolizumab plus cobimetinib, an MEK inhibitor in an unselected metastatic MSS CRC population.45,67